Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿ø¹ß¼º ÁßÃ߽Űæ°è ¸²ÇÁÁ¾ÀÇ Ki-67, p53, bcl-2 ¹ßÇö¿¡ µû¸¥ ¿¹ÈÄ ºÐ¼® Prognostic Implications of Ki-67 Labelling Index and p53, bcl-2 Protein Expression in the Primary Central Nervous System Lymphoma

´ëÇѺ´¸®ÇÐȸÁö 2000³â 34±Ç 6È£ p.456 ~ 464
ÇÑÀçÈ£, ¾ç¿ìÀÍ, ±èŽÂ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÇÑÀçÈ£ ( Han Jae-Ho ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

¾ç¿ìÀÍ ( Yang Woo-Ick ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èŽ ( Kim Tai-Seung ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


It has been claimed that CNS lymphoma, a rare neoplasm accounting for only a small fraction of malignant brain tumors, occurs with increasing frequency in immunologically normal as well as immunocompromised individuals. We investigated the prognostic value of Ki-67 index, p53, and bcl-2 oncoprotein expression in relation to the clinicopathological parameters in the primary CNS lymphoma patients. The tumors were graded by Kiel classification and the Working formulation and included 33 high-grade, 4 intermediate-grade, and 5 low-grade lymphomas. The phenotype was determined in 38 cases: 30 were B cell type and 8 were T cell type. All cases displayed variable degrees of nuclear Ki-67 staining from 1.0% to 92.0% (mean 51.1%). A highly significant correlation was established between the proportion of Ki-67 positive cells and the classification into grades (p=0.0002) and phenotypes (p=0.0002). Overexpression of p53 and bcl-2 protein was found in 37.1% and 51.4% of 35 patients, respectively. And p53 expression was significantly increased in B cell type (p=0.02). On Kaplan-Meier survival curve, the phenotype, grade of tumors, and p53 and bcl-2 protein expression were not correlated with overall survival. On multivariate analyses, overall survival was independently influenced by Ki-67 index. In conclusion, it is suggested that Ki-67 proliferating index is the most important marker for predicting biologic behavior of the primary CNS lymphoma.

Å°¿öµå

Central nervous system lymphoma;p53;bcl-2;Ki-67;Survival

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS